Rx Importation: Califf's Switch Means US FDA Commissioners No Longer Uniformly Opposed
In JAMA editorial, former FDA chief supports drug importation under narrow circumstances as a way to reduce drug prices, marking a shift from his previous stance on the issue and that of other past agency heads. Essay, co-authored by former CMS Acting Administrator Andy Slavitt, calls importation "a workaround born of desperation."
You may also be interested in...
Many of the products most commonly sighted as in need of a price break are not eligible under the legal framework described.
State is third to obtain approval from CMS to negotiate supplemental rebates as part of value-based contract. Arrangements would be exempt from “best price” requirements.
Legislation from Sens. Bill Cassidy and Mark Warner would eliminate barriers to value-based contracting for drugs reimbursed by public payers.